Editorial Perspective—Advances in B-Cell Non-Hodgkin's Lymphoma

Leukemia and Lymphoma

Volumn 44, Issue sup4, 2003, Pages S1-S4

  Hagenbeek, a ^a   Bischof Delaloye, a ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

131I Tositumomab (Bexxar ); 90Y Ibritumomab tiuxetan (Zevalin ); NHL; Radioimmunotherapy (RIT)

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE PHOSPHATE; IBRITUMOMAB TIUXETAN; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER CELL; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL STUDY; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; ISOTOPE LABELING; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY;

ALGORITHMS; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, B-CELL; RADIOIMMUNOTHERAPY;

EID: 1342287611     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190310001616908     Document Type: Article

References (23)

1. Harris, N.L. (1997) “Principles of the revised European-American Lymphoma Classification (from the International Lymphoma Study Group)”, Ann. Oncol., 8 (Suppl 2), 11 — 16.
2. Fisher, RI., Miller, T.P. and Grogan, T.M. (1998) “New REAL clinical entities”, Cancer J. Sci. Am., 4 (Suppl 2), S5—S12.
3. Jaffe, E.S., Harris, N.L., Diebold, J. and Muller-Hermelink, H.K. (1999) “World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report”, Am. J. Clin. Pathol., 111, S8 —S12.
4. Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, RI., et al. (2002) “The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lympho-ma”, N. Engl. J. Med., 346, 1937– 1947.
5. Coiffier, B. (2002) “Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lympho-ma”, Semin. Oncol., 29, 18 – 22.
6. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., et al. (2002) “CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma”, N. Engl. J. Med., 346, 235 – 242.
7. Seymour, J.F., Grigg, A.P., Szer, J. and Fox, R.M. (2001) “Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders”, Ann. Oncol., 12, 1455 — 1460.
8. McLaughlin, P., Hagemeister, F.B., Rodriguez, MA., Sarris, A.H., Pate, O., Younes, A., et al. (2000) “Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma”, Semin. Oncol., 27, 37 — 41.
9. Zinzani, P.L., Magagnoli, M., Bendandi, M., Gherlinzoni, F., Orcioni, G.F., Cellini, C., et al. (2000) “Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas”, Ann. Oncol., 11, 363 – 365.
10. Bosch, F., Ferrer, A., Lopez-Guillermo, A., Gine, E., Bellosillo, B., Villamor, N., et al. (2002) “Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia”, Br. J. Haematol., 119, 976 – 984.
11. Crawley, CR., Foran, J.M., Gupta, R.K., Rohatiner, AZ., Summers, K., Matthews, J., et al. (2000) “A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma”, Ann. Oncol., 11, 861 – 865.
12. Zinzani P.L. on behalf of an Italian Cooperative Study Group on Lymphoma (2002) “A randomised trial of fludarabine versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma”, Ann. Oncol., 13 \(Suppl 2), 57 (Abstract 185).
13. Cazin, B., Maloum, K., Divine, M., Lepretre, S., Travade, P., Delmer, A., et al. (2002) “Oral fludarabine and cyclophosphamide in previously untreated CLL: Preliminary data on 75 pts”, Blood, 100, 206a (Abstract 773).
14. Witzig, T.E., Flinn, I.W., Gordon, L.I., Emmanouilides, C., Czuczman, M.S., Saleh, M.N., et al. (2002) “Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with ritux-imab-refractory follicular non-Hodgkin's lymphoma”, J. Clin. Oncol., 20, 3262 — 3269.
15. Witzig, T.E., Gordon, L.I., Cabanillas, F., Czuczman, M.S., Emmanouilides, C., Joyce, R., et al. (2002) “Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunother-apy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodg-kin's lymphoma”, J. Clin. Oncol., 20, 2453 – 2463.
16. Kaminski, M.S., Estes, J., Zasadny, KR., Francis, I.R., Ross, C.W., Tuck, M., et al. (2000) “Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience”, Blood, 96, 1259 – 1266.
17. Kaminski, M.S., Zelenetz, A.D., Press, O.W., Saleh, M., Leonard, J., Fehrenbacher, L., et al. (2001) “Pivotal study of iodine 1131 tositumomab for chemotherapy-refractory low-grade or trans-formed low-grade B-cell non-Hodgkin's lymphomas”, J. Clin. Oncol., 19, 3918 — 3928.
18. Press, O.W., Eary, J.F., Appelbaum, FR., Martin, P.J., Badger, CC., Nelp, W.B., et al. (1993) “Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support”, N. Engl. J. Med., 329, 1219 – 1224.
19. Kaminski, M.S., Tuck, M., Regan, D., Kison, P. and Wahl, R.L. (2002) “High response rates and durable remissions in patients with previously untreated, advanced-stage, follicular lymphoma treated with tositumomab and iodine tositumomab (Bexxar)”, Blood, 100, 356a 1 – 131 (Abstract 1381).
20. Leonard, J., Coleman, M., Kostakoglu, L., Morris, A., Gregory, S., Link, B., et al. (2001) “Bexxar TM (iodine tositumomab and tositumomab) can be administered safely in sequential combination with chemotherapy in initial treatment of non-Hodgkins lymphoma (NHL)”, Proc. Am. Soc. Clin. Oncol., 20, 287a 1 – 131 (Abstract 1146).
21. Emmanouilides, C., Witzig, T., Molina, A., Gordon, L., Multani, P., Wiseman, G., et al. (2003) “Improved safety and efficacy of Y-90-ibritumomab tiuxetan (Zevalin) radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low grade, follicular and transformed B-cell non-Hodgkin's lymphoma (NHL)”, Proc. Am. Soc. Clin. Oncol., 22, 595 (Abstract 2392).
22. Gordon, L.I., Witzig, T.E., Emmanouilides, C., Raubitschek, A., Spies, S., Wiseman, G., et al. (2002) “90Y ibritumomab (Zevalin) in aggressive non-Hodgkin's lymphoma: analysis of response and toxicity”, Proc. Am. Soc. Clin. Oncol., 21, 266a (Abstract 1061).
23. Bartlett, N.L., Witzig, T.E., Gordon, L., Beck, T., Fehrenbacher, L., Kornmehl, E., et al. (2002) “90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin's lym-phoma (NHL) patients”, Proc. Am. Soc. Clin. Oncol., 21, 14a (Abstract 51).